Devices and Endoscopic Bariatric Therapies for Obesity
- 1 Downloads
Purpose of Review
In this review, we describe the FDA-approved and investigational devices and endoscopic bariatric therapies for the treatment of obesity. We focus on literature published in the past few years and present mechanisms of action as well as efficacy and safety data.
Devices and endoscopic procedures are emerging options to fill the significant treatment gap in the management of obesity. Not only are these devices and procedures minimally invasive and reversible, but they are potentially more effective than antiobesity medications, often safer for poor surgical candidates and possibly less expensive than bariatric surgery.
As many patients require a variety of management strategies (medications, devices, procedures, and/or surgery) in addition to lifestyle modifications to achieve clinically significant weight loss, the future of obesity treatment involves a multidisciplinary approach. Combinations of advanced treatment strategies can lead to additive or synergistic weight loss. This is an area that requires further investigation.
KeywordsObesity Devices Endoscopic bariatric therapy Intragastric balloon Aspiration therapy Vagal blockade
Compliance with Ethical Standards
Conflict of Interest
Katherine H. Saunders declares that she has no conflict of interest.
Leon I. Igel declares that he has no conflict of interest.
Monica Saumoy declares that she has no conflict of interest.
Reem Z. Sharaiha has received grant support from Apollo Endosurgery and Boston Scientific.
Louis J. Aronne has received research funding from Aspire Bariatrics, Eisai, and Takeda Pharmaceuticals. He declares consultant/advisory board work with Jamieson Labs, Pfizer, Novo Nordisk, Eisai, VIVUS, GI Dynamics, JOVIA Health, and Gelesis. He is a shareholder of Zafgen, Gelesis, MYOS Corporation, and Jamieson Labs, and he is on the Board of Directors of MYOS Corporation and Jamieson Labs.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of Particular Interest, Published Recently, Have Been Highlighted as: • Of Importance •• Of Major Importance
- 1.•• Jensen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014. 2013;63(25 Pt B):2985–3023. Drafted by a task force of experts from the American College of Cardiology, American Heart Association, and The Obesity Society, this publication is the first clinical practice guidelines for the management of adults with overweight and obesity.Google Scholar
- 6.•• Apovian CM, Aronne LJ, Bessesen DH, McDonnell M, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62. Drafted by an Endocrine Society-appointed task force of experts and co-sponsored by the European Society of Endocrinology and The Obesity Society, this publication is the first clinical practice guidelines for the pharmacologic management of obesity.CrossRefPubMedGoogle Scholar
- 9.Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641.Google Scholar
- 12.U.S. Food and Drug Administration. ORBERA™ Intragastric Balloon System - P140008. Available at: https://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm457416.htm. Accessed December 10, 2017.
- 14.U.S. Food and Drug Administration. ReShape Integrated Dual Balloon System - P140012. Available at: https://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm456293.htm. Accessed December 10, 2017.
- 15.Sullivan S, Swain JM, Woodman G, Edmundowicz S, Hassanein TI, Shayani V, et al. The obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. Gastroenterology. 2016;150(4 Suppl 1):S1267.CrossRefGoogle Scholar
- 16.U.S. Food and Drug Administration. Obalon Balloon System - P160001. Available at: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm520741.htm. Accessed December 10, 2017.
- 28.Bariatric Endoscopy Task Force ASGE, Technology Committee ASGE, Abu Dayeh BK, Kumar N, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.CrossRefGoogle Scholar
- 38.Astrup A, Kristensen M, Gnessi L, et al. Oral administration of Gelesis100, a novel hydrogel, significantly decreases body weight in overweight and obese subjects. In: Program of the Joint Meeting of the International Congress of Endocrinology and the Endocrine Society, June 21–24, 2014; Chicago, IL, USA. Abstract #0897. Available at: http://www.gelesis.com/pdf/Astrup-FLOW-Endocrine-Society-2014.pdf. Accessed September 23, 2017.
- 40.National Institute of Health U.S. National Library of Medicine. ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss. Available at: https://clinicaltrials.gov/ct2/show/NCT02518685. Accessed December 10, 2017.
- 48.Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017.Google Scholar
- 49.Lopez Nava G, Baustista Gastano I, Fernandez-Corbelle JP, et al. Endoscopic sleeve gastroplasty (the Apollo method): a new approach to obesity managmenet. Rev Esp Enferm Dig. 2016;108(4):201–6.Google Scholar
- 56.Hill C, Khashab MA, Kalloo AN et al. Endoluminal weight loss and metabolic therapies: current and future techniques. Ann N Y Acad Sci 2017.Google Scholar
- 74.Boi SK, Moore JX, Royston KJ, Demark-Wahnefried W. Letter to the editor: vagal blocking (vBloc) therapy: a new era of clinical therapy for extreme obesity : re: Apovian et al. two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial. Obesity surgery. 2016. Obes Surg. 2017;27(2):483–4.CrossRefPubMedPubMedCentralGoogle Scholar